Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data

Author:

Dhruva Sanket S.123,Parzynski Craig S.3,Gamble Ginger M.3,Curtis Jeptha P.34,Desai Nihar R.34,Yeh Robert W.5678,Masoudi Frederick A.9,Kuntz Richard10,Shaw Richard E.11,Marinac‐Dabic Danica12,Sedrakyan Art13,Normand Sharon‐Lise T.1415,Krumholz Harlan M.23416,Ross Joseph S.231617

Affiliation:

1. University of California, San Francisco, School of Medicine and San Francisco Veterans Affairs Healthcare System San Francisco CA

2. National Clinician Scholars Program Yale School of Medicine New Haven CT

3. Center for Outcomes Research and Evaluation Yale–New Haven Hospital New Haven CT

4. Section of Cardiovascular Medicine Department of Medicine, and National Clinician Scholars Program Yale School of Medicine New Haven CT

5. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology Boston MA

6. Division of Cardiovascular Medicine Beth Israel Deaconess Medical Center Boston MA

7. Harvard Medical School Boston MA

8. Baim Institute for Clinical Research Boston MA

9. Division of Cardiology Department of Medicine University of Colorado Anschutz Medical Campus Aurora CO

10. Medtronic, Inc. Minneapolis MN

11. Department of Clinical Informatics California Pacific Medical Center San Francisco CA

12. Office of Clinical Evidence and Analysis Center for Devices and Radiological Health U.S. Food and Drug Administration Silver Spring MD

13. Department of Health Policy and Research Weill Cornell Medicine New York Presbyterian Hospital New York NY

14. Department of Health Care Policy Harvard Medical School Boston MA

15. Department of Biostatistics Harvard T.H. Chan School of Public Health Harvard University Boston MA

16. Department of Health Policy and Management Yale School of Public Health New Haven CT

17. Section of General Medicine Department of Medicine, and National Clinician Scholars Program Yale School of Medicine New Haven CT

Abstract

Background More than 600 000 coronary stents are implanted during percutaneous coronary interventions ( PCI s) annually in the United States. Because no real‐world surveillance system exists to monitor their long‐term safety, claims data are often used for this purpose. The extent to which adverse events identified with claims data can be reasonably attributed to a specific medical device is uncertain. Methods and Results We used deterministic matching to link the NCDR (National Cardiovascular Data Registry) Cath PCI Registry to Medicare fee‐for‐service claims for patients aged ≥65 years who underwent PCI with drug‐eluting stents ( DESs ) between July 1, 2009 and December 31, 2013. We identified subsequent PCI s within 1 year of the index procedure in Medicare claims as potential safety events. We linked these subsequent PCI s back to the NCDR Cath PCI Registry to ascertain how often the revascularization could be reasonably attributed to the same coronary artery as the index PCI (ie, target vessel revascularization). Of 415 306 DES placements in 368 194 patients, 33 174 repeat PCI s were identified in Medicare claims within 1 year. Of these, 28 632 (86.3%) could be linked back to the NCDR Cath PCI Registry; 16 942 (51.1% of repeat PCI s) were target vessel revascularizations. Of these, 8544 (50.4%) were within a previously placed DES : 7652 for in‐stent restenosis and 1341 for stent thrombosis. Of 16 176 patients with a claim for acute myocardial infarction in the follow‐up period, 4446 (27.5%) were attributed to the same coronary artery in which the DES was implanted during the index PCI (ie, target vessel myocardial infarction). Of 24 288 patients whose death was identified in claims data, 278 (1.1%) were attributed to the same coronary artery in which the DES was implanted during the index PCI . Conclusions Most repeat PCI s following DES stent implantation identified in longitudinal claims data could be linked to real‐world registry data, but only half could be reasonably attributed to the same coronary artery as the index procedure. Attribution among those with acute myocardial infarction or who died was even less frequent. Safety signals identified using claims data alone will require more in‐depth examination to accurately assess stent safety.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference33 articles.

1. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011

2. Center for Devices and Radiological Health. Food and Drug Administration . CDRH Transparency: Total Product Life Cycle (TPLC). September 6 2018. Available at: https://www.fda.gov/about-fda/cdrh-transparency/cdrh-transparency-total-product-life-cycle-tplc. Accessed January 14 2020.

3. Need for a National Evaluation System for Health Technology

4. Center for Devices and Radiological Health. Food and Drug Administration . Use of Real‐World Evidence to Support Regulatory Decision‐Making for Medical Devices. Guidance Document. August 31 2017. Available at: https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf. Accessed January 14 2020.

5. Real-World Evidence — What Is It and What Can It Tell Us?

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3